semaglutide and ckd in patients with overweight or obesity chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide in Diabetic Kidney Disease:

Ready to start semaglutide treatment

Dehydration from gastrointestinal side effects may also play a role

Small case numbers mean that statistics can shift quickly, as noted by Rizzo

They highlight why awareness, monitoring, and a long-term plan are crucial when considering medication as part of an overall health strategy

Rodriguez hopes to gradually reduce the frequency of her doses further, going down to once every three weeks then hopefully four provided she can maintain her weight

Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data